Keyphrases
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
100%
Urokinase-type Plasminogen Activator
44%
Cancer Diagnostics
22%
Tumor Progression
22%
Urokinase Plasminogen Activator System
22%
Tumor Angiogenesis
22%
Oncology Drug Development
22%
Small Molecules
11%
Clinical Trials
11%
Molecular Targets
11%
Signaling Pathway
11%
Extracellular Matrix Protein 1 (ECM1)
11%
Tumor
11%
Cell Adhesion
11%
In Vivo Data
11%
Cell Surface
11%
Plasmin
11%
Zymogen
11%
Serine Protease
11%
Integrin
11%
Cell Motility
11%
Anticancer Drugs
11%
Occupancy
11%
Cell Surface Receptor
11%
Cancer Development
11%
Clinical Issues
11%
Cancer Therapeutic Agents
11%
Promising Target
11%
Suitable Target
11%
Pleiotropic Effects
11%
Signal Transducing
11%
Diagnostics Development
11%
Diagnostic Agents
11%
Active Site Inhibitors
11%
Surface Activation
11%
Matrix Strategy
11%
Therapeutic Rationale
11%
Medicine and Dentistry
Malignant Neoplasm
100%
Urokinase Receptor
100%
Urokinase
75%
Prourokinase
50%
Tumor Progression
25%
Angiogenesis
25%
Neoplasm
12%
Fibrinolysin
12%
In Vitro
12%
Cell Surface
12%
Cell Motility
12%
Target Cell
12%
Cell Surface Receptor
12%
Serine Proteinase
12%
Enzyme Precursor
12%
Cell Signaling Pathway
12%
Diagnostic Agent
12%
Integrin
12%
Clinical Trial
12%
Scleroprotein
12%
Cell Migration
12%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Urokinase Receptor
100%
Urokinase
75%
Prourokinase
50%
Tumor Growth
25%
Molecular Target
12%
Cancer Drug Development
12%
Clinical Trial
12%
Integrin
12%
Cell Surface Receptor
12%
Serine Proteinase
12%
Diagnostic Agent
12%
Plasmin
12%
Enzyme Precursor
12%
Neoplasm
12%
Scleroprotein
12%
Immunology and Microbiology
Urokinase Receptor
100%
Cell Surface
25%
Angiogenesis
25%
Matrix Protein
12%
Target Cell
12%
Cell Motility
12%
Extracellular Matrix
12%
Cell Migration
12%
Plasmin
12%
Serine
12%
Integrin
12%